The DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index.
Neoadjuvant therapy for pancreatic cancer
Abstract
Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with surgical resection of the primary tumour and systemic chemotherapy, which provides considerably longer overall survival (OS) durations than either modality alone. Regardless, most patients will have disease relapse owing to micrometastatic disease. Although currently a matter of some debate, considerable research interest has been focused on the role of neoadjuvant therapy for all forms of resectable PDAC. Whilst adjuvant combination chemotherapy remains the standard of care for patients with resectable PDAC, neoadjuvant chemotherapy seems to improve OS without necessarily increasing the resection rate in those with borderline-resectable disease. Furthermore, around 20% of patients with unresectable non-metastatic PDAC might undergo resection following 4-6 months of induction combination chemotherapy with or without radiotherapy, even in the absence of a clear radiological response, leading to improved OS outcomes in this group. Distinct molecular and biological responses to different types of therapies need to be better understood in order to enable the optimal sequencing of specific treatment modalities to further improve OS. In this Review, we describe current treatment strategies for the various clinical stages of PDAC and discuss developments that are likely to determine the optimal sequence of multimodality therapies by integrating the fundamental clinical and molecular features of the…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For other cancer types, such as pancreatic ductal adenocarcinoma117, the results from clinical trials are contradictory.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [117]
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J. H., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055531 · Cited by 6,334
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Research works printed but not linked: 1
- Amin, M. B. et al. (eds) AJCC Cancer Staging Manual 8th edn (Springer, 2017).
Cited by
Therapeutic developments in pancreatic cancer
Hu, Z. I., & O’Reilly, E. M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 413
“For patients with resectable PDAC, the question of whether perioperative chemotherapy improves overall survival compared with upfront surgery with adjuvant chemotherapy is an area of active research 10,11 .”
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
“For other cancer types, such as pancreatic ductal adenocarcinoma 117 , the results from clinical trials are contradictory.”
Walker, H. L., Ghani, S., Kuemmerli, C., Nebiker, C. A., Müller, B. P., Raptis, D. A., & Staubli, S. M. (2023) · Journal of Medical Internet Research · doi:10.2196/47479 · Cited by 363
“Furthermore, the role of radiotherapy in the treatment of pancreatic cancer is limited to specific clinical scenarios and is subject to debate, which ChatGPT does not highlight [27].”
Labori, K. J., Bratlie, S. O., Andersson, B., Angelsen, J.-H., Biörserud, C., Björnsson, B., Bringeland, E. A., Elander, N., Garresori, H., Grønbech, J. E., et al. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00405-3 · Cited by 225
Stoop, T. F., Theijse, R. T., Seelen, L. W. F., Groot Koerkamp, B., van Eijck, C. H. J., Wolfgang, C. L., van Tienhoven, G., van Santvoort, H. C., Molenaar, I. Q., Wilmink, J. W., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00856-2 · Cited by 201
“…borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC), mainly according to the presence and extent of tumour involvement with major visceral vasculature (that is, superior mesenteric artery, coeliac axis, hepatic artery and portomesenteric venous axis ) 4 .”
Self-citation
Metadata
- Authors
- Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J.
- Affiliations
- University Hospital Heidelberg (DE)
- Cedars-Sinai Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Wayne State University (US)
- Harvard University (US)
- University Medical Center Hamburg-Eppendorf (DE)
- Heidelberg University (DE)
- Corresponding author
- Neoptolemos, John
- ORCID
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2023-03-17
- Volume
- 20
- Issue
- 5
- Pages
- 318-337
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W4327697352
- Cited by
- 377
- References
- 162
- Citations by year
- 2026: 76 · 2025: 129 · 2024: 125 · 2023: 46
- FWCI
- 12.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Keywords
- pancreatic ductal adenocarcinoma, neoadjuvant therapy, borderline resectable pancreatic cancer, unresectable pancreatic cancer, combination chemotherapy, induction chemotherapy, chemoradiotherapy, surgical resection, adjuvant chemotherapy, overall survival, micrometastatic disease
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasm Recurrence, Local, Pancreatic Neoplasms, Neoadjuvant Therapy, Carcinoma, Pancreatic Ductal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neoadjuvant therapy for pancreatic cancer. https://app.cochat.ai/papers/10.1038/s41571-023-00746-1
- The paper
- Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J. (2023). Neoadjuvant therapy for pancreatic cancer. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-023-00746-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.